Zimmer Biomet (NYSE:ZBH) Given Neutral Rating at BTIG Research

NodeGuardian · 2026-03-24T03:31:51+00:00

BTIG Research maintains a "neutral" rating on Zimmer Biomet, which recently exceeded earnings expectations with an EPS of $2.42. Analysts predict a price target of $106.20, and despite insider stock sales, institutional ownership is strong at 88.89%.

NodeGuardian

2026-03-24 03:31:51

Abstract generation in progress

BTIG Research has reiterated a “neutral” rating for Zimmer Biomet (NYSE:ZBH), with analysts holding a consensus “Hold” rating and an average price target of $106.20. The medical equipment provider recently beat quarterly earnings expectations with $2.42 EPS and $2.24 billion in revenue, and has issued FY2026 EPS guidance of $8.30–$8.45. Despite an insider stock sale, institutional ownership remains high at 88.89%.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.